Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation

Boriani, Giuseppe; Biffi, Mauro; Frabetti, L; Azzolini, U; Sabbatani, Paolo; Bronzetti, Gabriele; Capucci, Alessandro; Magnani, B

doi:10.1016/s0002-8703(96)90098-8

Cited by 51 publications

(24 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Administration of intravenous amiodarone, adenosine, digoxin (oral or intravenous), or nondihydropyridine calcium channel antagonists (oral or intravenous) in patients with WPW syndrome who have pre-excited AF is potentially harmful as they accelerate the ventricular rate (493-495). (Level of Evidence: B) …”

Section: Specific Patient Groups and Afmentioning

confidence: 99%

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

January¹,

Wann²,

Alpert³

et al. 2014

Circulation

3,581

1,139

View full text Add to dashboard Cite

Section: Specific Patient Groups and Afmentioning

confidence: 99%

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

January¹,

Wann²,

Alpert³

et al. 2014

Circulation

3,581

1,139

View full text Add to dashboard Cite

“…The failure to prevent an increased ventricular response leads the study to call for the establishment of the safety of amiodarone in WPW-AF [5]. The findings support the notion that amiodarone may not be the safe pharmacological treatment of choice for rate control in WPW-AF [2,4,5,13,16].…”

Section: Discussionmentioning

confidence: 69%

“…The 1996 Boriani case report concludes that amiodarone may lead to prodysrhythmic events in WPW-AF. The case report recommends the use of class 1A or 1C antidysrhythmic drugs in place of amiodarone in WPW-AF [2]. Similarly, in 2005, Tijunelis and Herbert published a review article on amiodarone in WPW-AF, arguing against the further use of amiodarone.…”

Section: Discussionmentioning

confidence: 99%

“…Amiodarone's relatively benign side-effect profile likely plays a role in the AHA recommendations. However, it is unclear whether this endorsement takes into consideration that amiodarone can cause ventricular fibrillation in a small but significant number of cases [2,16], or that amiodarone is simply not efficacious in a number of wide-complex tachycardia cases [3,8]. Despite procainamide's potential for WPW-AF control, it has significant side effects, including hypotension [3,4].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation

et al. 2010

View full text Add to dashboard Cite

The objective of this review is to explore and challenge the superiority of amiodarone for rate control in Wolff-Parkinson-White syndrome and concomitant atrial fibrillation (WPW-AF). The current recommendation for pharmacological treatment of this condition is amiodarone. A review of the past 25 years of literature finds several studies that identify a small risk of ventricular fibrillation secondary to amiodarone administration for rate control in WPW-AF. Additionally, the literature supports the safe and effective use of procainamide for rate control in WPW-AF. This review concludes that amiodarone is not superior to procainamide in rate control for WPW-AF, and may be dangerous.

show abstract

“…Although amiodarone is recommended by the AHA's Advanced Cardiac Life Support guidelines, several articles warn against this treatment. [29][30][31] Long-term treatment with antiarrhythmic agents is undesirable for patients with WPW who are at risk of lethal arrhythmias. Thus, radiofrequency catheter ablation of the accessory pathway, with its high success rate (95%) and low complication rate, is the treatment of choice for both symptomatic and asymptomatic patients at high risk for arrhythmias.…”

Section: Wolff-parkinson-white Syndrome (Pre-excitation)mentioning

confidence: 99%

Causes of Sudden Cardiac Arrest in Young Athletes

Westrol

Kapitanyan

Marques-Baptista

et al. 2010

Postgraduate Medicine

View full text Add to dashboard Cite

Knowledge of sudden cardiac death in young athletes is imperative for all physicians and allied health professionals. The complete differential diagnosis of a young patient with sudden cardiac arrest will result in proper work-up and treatment. In this article, we review several etiologies of sudden cardiac death, including hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, Wolff-Parkinson-White syndrome, long QT syndrome, Brugada syndrome, and commotio cordis. Clinical findings, work-up, treatment, long-term management, and athlete preparticipation screening guidelines are discussed.

show abstract

Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation

Cited by 51 publications

References 9 publications

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation

Causes of Sudden Cardiac Arrest in Young Athletes

Contact Info

Product

Resources

About